Indacaterol/Glycopyrronium/Mometasone fixed dose combination for uncontrolled asthma
Expert Rev Respir Med. 2021 Nov 30. doi: 10.1080/17476348.2021.2011222. Online ahead of print.ABSTRACTINTRODUCTION: Asthma symptoms can be relieved through a maintenance treatment combining long-acting β2-agonist and inhaled corticosteroids (LABA/ICS). However, for patients with inadequately controlled asthma, the LABA/ICS combination might not be sufficient. Under these conditions, clinical guidelines recommend the administration of inhaled long-acting muscarinic antagonists (LAMA) as an add-on therapy to LABA/ICS to better control asthma and improve lung function. For nearly two decades, the only LAMA to be approved...
Source: Expert Review of Respiratory Medicine - November 30, 2021 Category: Respiratory Medicine Authors: Corrado Pelaia Claudia Crimi Nunzio Crimi Luisa Ricciardi Nicola Scichilone Giuseppe Valenti Ornella Bonavita Stefano Andaloro Paolo Morini Andrea Rizzi Girolamo Pelaia Source Type: research

Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension
Expert Rev Respir Med. 2021 Nov 30. doi: 10.1080/17476348.2022.2011220. Online ahead of print.ABSTRACTINTRODUCTION: Intravenous prostacyclin-analogs (PCA, e.g. epoprostenol, treprostinil, iloprost) have become an essential part in the therapy of patients with pulmonary hypertension (PH), mainly pulmonary arterial hypertension (PAH). They show considerable differences in pharmacology. A combination therapy including intravenous drugs is regarded as the "gold standard" in most of PAH patients.AREAS COVERED: This review discusses and summarizes the studies and concepts on which this therapy is based. To date, intrav...
Source: Expert Review of Respiratory Medicine - November 30, 2021 Category: Respiratory Medicine Authors: Ralf Ewert Dirk Habedank Michael Halank Beate Stubbe Christian F Opitz Source Type: research

Indacaterol/Glycopyrronium/Mometasone fixed dose combination for uncontrolled asthma
Expert Rev Respir Med. 2021 Nov 30. doi: 10.1080/17476348.2021.2011222. Online ahead of print.ABSTRACTINTRODUCTION: Asthma symptoms can be relieved through a maintenance treatment combining long-acting β2-agonist and inhaled corticosteroids (LABA/ICS). However, for patients with inadequately controlled asthma, the LABA/ICS combination might not be sufficient. Under these conditions, clinical guidelines recommend the administration of inhaled long-acting muscarinic antagonists (LAMA) as an add-on therapy to LABA/ICS to better control asthma and improve lung function. For nearly two decades, the only LAMA to be approved...
Source: Expert Review of Respiratory Medicine - November 30, 2021 Category: Respiratory Medicine Authors: Corrado Pelaia Claudia Crimi Nunzio Crimi Luisa Ricciardi Nicola Scichilone Giuseppe Valenti Ornella Bonavita Stefano Andaloro Paolo Morini Andrea Rizzi Girolamo Pelaia Source Type: research

Strategies for optimizing intravenous prostacyclin-analog therapy in patients with pulmonary arterial hypertension
Expert Rev Respir Med. 2021 Nov 30. doi: 10.1080/17476348.2022.2011220. Online ahead of print.ABSTRACTINTRODUCTION: Intravenous prostacyclin-analogs (PCA, e.g. epoprostenol, treprostinil, iloprost) have become an essential part in the therapy of patients with pulmonary hypertension (PH), mainly pulmonary arterial hypertension (PAH). They show considerable differences in pharmacology. A combination therapy including intravenous drugs is regarded as the "gold standard" in most of PAH patients.AREAS COVERED: This review discusses and summarizes the studies and concepts on which this therapy is based. To date, intrav...
Source: Expert Review of Respiratory Medicine - November 30, 2021 Category: Respiratory Medicine Authors: Ralf Ewert Dirk Habedank Michael Halank Beate Stubbe Christian F Opitz Source Type: research

Indacaterol/Glycopyrronium/Mometasone fixed dose combination for uncontrolled asthma
Expert Rev Respir Med. 2021 Nov 30. doi: 10.1080/17476348.2021.2011222. Online ahead of print.ABSTRACTINTRODUCTION: Asthma symptoms can be relieved through a maintenance treatment combining long-acting β2-agonist and inhaled corticosteroids (LABA/ICS). However, for patients with inadequately controlled asthma, the LABA/ICS combination might not be sufficient. Under these conditions, clinical guidelines recommend the administration of inhaled long-acting muscarinic antagonists (LAMA) as an add-on therapy to LABA/ICS to better control asthma and improve lung function. For nearly two decades, the only LAMA to be approved...
Source: Expert Review of Respiratory Medicine - November 30, 2021 Category: Respiratory Medicine Authors: Corrado Pelaia Claudia Crimi Nunzio Crimi Luisa Ricciardi Nicola Scichilone Giuseppe Valenti Ornella Bonavita Stefano Andaloro Paolo Morini Andrea Rizzi Girolamo Pelaia Source Type: research

Non-invasive ventilation in patients with covid-19 from the perspective of the risk of contamination: a narrative review
Expert Rev Respir Med. 2021 Nov 26. doi: 10.1080/17476348.2021.2011223. Online ahead of print.ABSTRACTINTRODUCTION: Non-invasive ventilation (NIV) can be a useful resource to treat acute respiratory failure (ARF), which occurs in patients with COVID-19. However, it is important to consider that there are still no clinical studies that have verified the safety of its use in increase of contamination.AREAS COVERED: Given the potential benefits and simultaneous concerns over the use of NIV in patients with COVID-19, further inquiry is necessary to reach a clinical consensus and provide recommendations for safe use, avoiding c...
Source: Expert Review of Respiratory Medicine - November 26, 2021 Category: Respiratory Medicine Authors: Murilo Rezende Oliveira Guilherme Dionir Back Vanessa de Mello Konzen Adriana S Garcia de Ara újo C ássia da Luz Goulart Rebeca Nunes Silva Lia Mara Wibelinger Snehil Dixit Ross Arena Audrey Borghi-Silva Source Type: research

Diagnostic value of fractional exhaled nitric oxide in differentiating the Asthma-COPD overlap from COPD: a systematic review and meta-analysis
ConclusionFeNO as an inflammatory biomarker is effective in differentiating ACO from COPD and assisting in clinical decision-making.PMID:34821171 | DOI:10.1080/17476348.2022.2011221 (Source: Expert Review of Respiratory Medicine)
Source: Expert Review of Respiratory Medicine - November 25, 2021 Category: Respiratory Medicine Authors: Chuchu Zhang Meng Zhang Yalei Wang Xiaojie Su Ting Lei Haichuan Yu Jian Liu Source Type: research

Blood eosinophils in COPD: Friend or foe?
Expert Rev Respir Med. 2021 Nov 25. doi: 10.1080/17476348.2021.2011219. Online ahead of print.ABSTRACTINTRODUCTION: The pathogenesis of Chronic obstructive pulmonary disease (COPD) is highly complex and the underlying cellular and molecular mechanisms remain poorly understood.AREAS COVERED: COPD has been traditionally associated with neutrophilic inflammation of the bronchi, but in the last decade studies have demonstrated that eosinophils may also migrate into the lower airways of patients with COPD and their increased numbers can be noticed during exacerbations as well as stable disease. In this review, we present clinic...
Source: Expert Review of Respiratory Medicine - November 25, 2021 Category: Respiratory Medicine Authors: Anastasia Papaporfyriou Petros Bakakos Georgios Hillas Andriana I Papaioannou Stelios Loukides Source Type: research

Current opinion and comparison of surgical procedures for the treatment of primary spontaneous pneumothorax
Expert Rev Respir Med. 2021 Nov 25. doi: 10.1080/17476348.2022.2011218. Online ahead of print.ABSTRACTINTRODUCTION: Although three-port video-assisted thoracoscopic surgery (VATS) is the standard radical treatment for primary spontaneous pneumothorax (PSP), several issues need to be addressed as the postoperative recurrence rate remains relatively high. Although bullectomy is effective in preventing the postoperative recurrence of PSP, recurrent pneumothorax often occurs, requiring additional methods such as pleural covering with absorbable mesh sheets, surgical chemical pleurodesis, pleural abrasion, or pleurectomy. In ad...
Source: Expert Review of Respiratory Medicine - November 25, 2021 Category: Respiratory Medicine Authors: Kenji Tsuboshima Masatoshi Kurihara Kuniaki Seyama Source Type: research

Occupational chronic obstructive pulmonary disorder: prevalence and prevention
Expert Rev Respir Med. 2021 Nov 25. doi: 10.1080/17476348.2021.2011722. Online ahead of print.ABSTRACTINTRODUCTION: Occupational chronic obstructive pulmonary disorder, i.e. work-related asthma (WRA) and occupational chronic obstructive pulmonary disease (COPD), are the most common occupational lung diseases in the last decades worldwide. As in the case of the other occupational disorders, these diseases may be prevented.AREAS COVERED: WRA is a heterogeneous entity that includes three subtypes, immunologic occupational asthma (OA), irritant-induced asthma (IIA) and work-exacerbated asthma (WEA), depending on the role of oc...
Source: Expert Review of Respiratory Medicine - November 25, 2021 Category: Respiratory Medicine Authors: Jordan Minov Source Type: research

Diagnostic value of fractional exhaled nitric oxide in differentiating the Asthma-COPD overlap from COPD: a systematic review and meta-analysis
ConclusionFeNO as an inflammatory biomarker is effective in differentiating ACO from COPD and assisting in clinical decision-making.PMID:34821171 | DOI:10.1080/17476348.2022.2011221 (Source: Expert Review of Respiratory Medicine)
Source: Expert Review of Respiratory Medicine - November 25, 2021 Category: Respiratory Medicine Authors: Chuchu Zhang Meng Zhang Yalei Wang Xiaojie Su Ting Lei Haichuan Yu Jian Liu Source Type: research

Blood eosinophils in COPD: Friend or foe?
Expert Rev Respir Med. 2021 Nov 25. doi: 10.1080/17476348.2021.2011219. Online ahead of print.ABSTRACTINTRODUCTION: The pathogenesis of Chronic obstructive pulmonary disease (COPD) is highly complex and the underlying cellular and molecular mechanisms remain poorly understood.AREAS COVERED: COPD has been traditionally associated with neutrophilic inflammation of the bronchi, but in the last decade studies have demonstrated that eosinophils may also migrate into the lower airways of patients with COPD and their increased numbers can be noticed during exacerbations as well as stable disease. In this review, we present clinic...
Source: Expert Review of Respiratory Medicine - November 25, 2021 Category: Respiratory Medicine Authors: Anastasia Papaporfyriou Petros Bakakos Georgios Hillas Andriana I Papaioannou Stelios Loukides Source Type: research

Current opinion and comparison of surgical procedures for the treatment of primary spontaneous pneumothorax
Expert Rev Respir Med. 2021 Nov 25. doi: 10.1080/17476348.2022.2011218. Online ahead of print.ABSTRACTINTRODUCTION: Although three-port video-assisted thoracoscopic surgery (VATS) is the standard radical treatment for primary spontaneous pneumothorax (PSP), several issues need to be addressed as the postoperative recurrence rate remains relatively high. Although bullectomy is effective in preventing the postoperative recurrence of PSP, recurrent pneumothorax often occurs, requiring additional methods such as pleural covering with absorbable mesh sheets, surgical chemical pleurodesis, pleural abrasion, or pleurectomy. In ad...
Source: Expert Review of Respiratory Medicine - November 25, 2021 Category: Respiratory Medicine Authors: Kenji Tsuboshima Masatoshi Kurihara Kuniaki Seyama Source Type: research

Occupational chronic obstructive pulmonary disorder: prevalence and prevention
Expert Rev Respir Med. 2021 Nov 25. doi: 10.1080/17476348.2021.2011722. Online ahead of print.ABSTRACTINTRODUCTION: Occupational chronic obstructive pulmonary disorder, i.e. work-related asthma (WRA) and occupational chronic obstructive pulmonary disease (COPD), are the most common occupational lung diseases in the last decades worldwide. As in the case of the other occupational disorders, these diseases may be prevented.AREAS COVERED: WRA is a heterogeneous entity that includes three subtypes, immunologic occupational asthma (OA), irritant-induced asthma (IIA) and work-exacerbated asthma (WEA), depending on the role of oc...
Source: Expert Review of Respiratory Medicine - November 25, 2021 Category: Respiratory Medicine Authors: Jordan Minov Source Type: research

Inhaled interferons beta and SARS-COV2 infection: a preliminary therapeutic perspective
Expert Rev Respir Med. 2021 Nov 18. doi: 10.1080/17476348.2022.2008910. Online ahead of print.ABSTRACTIntroduction: SARS-COV2 infection represents a therapeutic challenge due to the limited number of effective therapies available and due the fact that it is not clear which host response in terms of inflammation pattern is the most predictive for an optimal (and rapid) recovery. Interferon β pathway is impaired in SARS-COV2 infection and this is associated with a bigger disease burden. Exogenous inhaled interferon might be beneficial in this setting.Areas covered: nebulized interferon-β is currently investigated a...
Source: Expert Review of Respiratory Medicine - November 18, 2021 Category: Respiratory Medicine Authors: Elena Cojocaru Cristian Cojocaru Sabina Antoniu Celina Silvia Stafie Armand Rajnoveanu Ruxandra Rajnoveanu Source Type: research

Inhaled indacaterol/glycopyrronium/mometasone furoate fixed-dose combination in moderate-to-severe asthma
Expert Rev Respir Med. 2021 Nov 16. doi: 10.1080/17476348.2021.2005585. Online ahead of print.ABSTRACTINTRODUCTION: Fixed-dose long-acting beta2-agonist (LABA)/inhaled corticosteroid (ICS) combinations and add-on therapies as needed are the mainstay for maintenance therapy in asthma. However, more than 40% of patients have an inadequately controlled disease. The development of triple fixed-dose combinations consisting of long-acting muscarinic antagonist (LAMA)/LABA/ICS has paved the way for a new approach to reach therapeutic goals of an optimal control of symptoms and an effective prevention of future exacerbations.AREAS...
Source: Expert Review of Respiratory Medicine - November 16, 2021 Category: Respiratory Medicine Authors: Luis P érez de Llano Elsa Naval Natalia Mej ía Javier Dom ínguez-Ortega Source Type: research

"The emerging role of mycophenolate mofetil in interstitial lung diseases"
Expert Rev Respir Med. 2021 Nov 11. doi: 10.1080/17476348.2021.2001331. Online ahead of print.ABSTRACTINTRODUCTION: Mycophenolate mofetil (MMF), initially approved to prevent rejection in solid organ allograft, is now being increasingly used for other conditions. Over the last decade, MMF has emerged as a useful therapy for a variety of immune-mediated diseases.AREAS COVERED: There has been a growing interest in the clinical use of MMF in the treatment of ILDs due to its versatile anti-inflammatory, immunomodulatory, anti-fibrotic and anti-proliferative properties. In this focussed review, we summarise the available litera...
Source: Expert Review of Respiratory Medicine - November 11, 2021 Category: Respiratory Medicine Authors: Kevin K Brown Sujeet Kulaprath Rajan Padmanabha Shenoy Monali Mehta Meena Lopez Rashmi Sharath Hegde Jaideep Gogtay Source Type: research

A Critical Review of the Respiratory Benefits and Harms of Orally Administered Opioids for Dyspnea Management in COPD
Expert Rev Respir Med. 2021 Nov 11. doi: 10.1080/17476348.2021.2005584. Online ahead of print.ABSTRACTINTRODUCTION: Dyspnea occurring in chronic obstructive pulmonary disease (COPD) that is refractory to traditional management strategies is a common and challenging problem. Considerable attention has been paid to the off-label use of orally administered opioids as a pharmacotherapy option for refractory dyspnea in COPD. Multiple professional respiratory society guidelines express support for the application of oral opioids for this purpose.AREAS COVERED: This manuscript will critically review randomized controlled trials u...
Source: Expert Review of Respiratory Medicine - November 11, 2021 Category: Respiratory Medicine Authors: Nicholas T Vozoris Source Type: research

"The emerging role of mycophenolate mofetil in interstitial lung diseases"
Expert Rev Respir Med. 2021 Nov 11. doi: 10.1080/17476348.2021.2001331. Online ahead of print.ABSTRACTINTRODUCTION: Mycophenolate mofetil (MMF), initially approved to prevent rejection in solid organ allograft, is now being increasingly used for other conditions. Over the last decade, MMF has emerged as a useful therapy for a variety of immune-mediated diseases.AREAS COVERED: There has been a growing interest in the clinical use of MMF in the treatment of ILDs due to its versatile anti-inflammatory, immunomodulatory, anti-fibrotic and anti-proliferative properties. In this focussed review, we summarise the available litera...
Source: Expert Review of Respiratory Medicine - November 11, 2021 Category: Respiratory Medicine Authors: Kevin K Brown Sujeet Kulaprath Rajan Padmanabha Shenoy Monali Mehta Meena Lopez Rashmi Sharath Hegde Jaideep Gogtay Source Type: research

A Critical Review of the Respiratory Benefits and Harms of Orally Administered Opioids for Dyspnea Management in COPD
Expert Rev Respir Med. 2021 Nov 11. doi: 10.1080/17476348.2021.2005584. Online ahead of print.ABSTRACTINTRODUCTION: Dyspnea occurring in chronic obstructive pulmonary disease (COPD) that is refractory to traditional management strategies is a common and challenging problem. Considerable attention has been paid to the off-label use of orally administered opioids as a pharmacotherapy option for refractory dyspnea in COPD. Multiple professional respiratory society guidelines express support for the application of oral opioids for this purpose.AREAS COVERED: This manuscript will critically review randomized controlled trials u...
Source: Expert Review of Respiratory Medicine - November 11, 2021 Category: Respiratory Medicine Authors: Nicholas T Vozoris Source Type: research

"The emerging role of mycophenolate mofetil in interstitial lung diseases"
Expert Rev Respir Med. 2021 Nov 11. doi: 10.1080/17476348.2021.2001331. Online ahead of print.ABSTRACTINTRODUCTION: Mycophenolate mofetil (MMF), initially approved to prevent rejection in solid organ allograft, is now being increasingly used for other conditions. Over the last decade, MMF has emerged as a useful therapy for a variety of immune-mediated diseases.AREAS COVERED: There has been a growing interest in the clinical use of MMF in the treatment of ILDs due to its versatile anti-inflammatory, immunomodulatory, anti-fibrotic and anti-proliferative properties. In this focussed review, we summarise the available litera...
Source: Expert Review of Respiratory Medicine - November 11, 2021 Category: Respiratory Medicine Authors: Kevin K Brown Sujeet Kulaprath Rajan Padmanabha Shenoy Monali Mehta Meena Lopez Rashmi Sharath Hegde Jaideep Gogtay Source Type: research

A Critical Review of the Respiratory Benefits and Harms of Orally Administered Opioids for Dyspnea Management in COPD
Expert Rev Respir Med. 2021 Nov 11. doi: 10.1080/17476348.2021.2005584. Online ahead of print.ABSTRACTINTRODUCTION: Dyspnea occurring in chronic obstructive pulmonary disease (COPD) that is refractory to traditional management strategies is a common and challenging problem. Considerable attention has been paid to the off-label use of orally administered opioids as a pharmacotherapy option for refractory dyspnea in COPD. Multiple professional respiratory society guidelines express support for the application of oral opioids for this purpose.AREAS COVERED: This manuscript will critically review randomized controlled trials u...
Source: Expert Review of Respiratory Medicine - November 11, 2021 Category: Respiratory Medicine Authors: Nicholas T Vozoris Source Type: research

"The emerging role of mycophenolate mofetil in interstitial lung diseases"
Expert Rev Respir Med. 2021 Nov 11. doi: 10.1080/17476348.2021.2001331. Online ahead of print.ABSTRACTINTRODUCTION: Mycophenolate mofetil (MMF), initially approved to prevent rejection in solid organ allograft, is now being increasingly used for other conditions. Over the last decade, MMF has emerged as a useful therapy for a variety of immune-mediated diseases.AREAS COVERED: There has been a growing interest in the clinical use of MMF in the treatment of ILDs due to its versatile anti-inflammatory, immunomodulatory, anti-fibrotic and anti-proliferative properties. In this focussed review, we summarise the available litera...
Source: Expert Review of Respiratory Medicine - November 11, 2021 Category: Respiratory Medicine Authors: Kevin K Brown Sujeet Kulaprath Rajan Padmanabha Shenoy Monali Mehta Meena Lopez Rashmi Sharath Hegde Jaideep Gogtay Source Type: research

A Critical Review of the Respiratory Benefits and Harms of Orally Administered Opioids for Dyspnea Management in COPD
Expert Rev Respir Med. 2021 Nov 11. doi: 10.1080/17476348.2021.2005584. Online ahead of print.ABSTRACTINTRODUCTION: Dyspnea occurring in chronic obstructive pulmonary disease (COPD) that is refractory to traditional management strategies is a common and challenging problem. Considerable attention has been paid to the off-label use of orally administered opioids as a pharmacotherapy option for refractory dyspnea in COPD. Multiple professional respiratory society guidelines express support for the application of oral opioids for this purpose.AREAS COVERED: This manuscript will critically review randomized controlled trials u...
Source: Expert Review of Respiratory Medicine - November 11, 2021 Category: Respiratory Medicine Authors: Nicholas T Vozoris Source Type: research

"The emerging role of mycophenolate mofetil in interstitial lung diseases"
Expert Rev Respir Med. 2021 Nov 11. doi: 10.1080/17476348.2021.2001331. Online ahead of print.ABSTRACTINTRODUCTION: Mycophenolate mofetil (MMF), initially approved to prevent rejection in solid organ allograft, is now being increasingly used for other conditions. Over the last decade, MMF has emerged as a useful therapy for a variety of immune-mediated diseases.AREAS COVERED: There has been a growing interest in the clinical use of MMF in the treatment of ILDs due to its versatile anti-inflammatory, immunomodulatory, anti-fibrotic and anti-proliferative properties. In this focussed review, we summarise the available litera...
Source: Expert Review of Respiratory Medicine - November 11, 2021 Category: Respiratory Medicine Authors: Kevin K Brown Sujeet Kulaprath Rajan Padmanabha Shenoy Monali Mehta Meena Lopez Rashmi Sharath Hegde Jaideep Gogtay Source Type: research

A Critical Review of the Respiratory Benefits and Harms of Orally Administered Opioids for Dyspnea Management in COPD
Expert Rev Respir Med. 2021 Nov 11. doi: 10.1080/17476348.2021.2005584. Online ahead of print.ABSTRACTINTRODUCTION: Dyspnea occurring in chronic obstructive pulmonary disease (COPD) that is refractory to traditional management strategies is a common and challenging problem. Considerable attention has been paid to the off-label use of orally administered opioids as a pharmacotherapy option for refractory dyspnea in COPD. Multiple professional respiratory society guidelines express support for the application of oral opioids for this purpose.AREAS COVERED: This manuscript will critically review randomized controlled trials u...
Source: Expert Review of Respiratory Medicine - November 11, 2021 Category: Respiratory Medicine Authors: Nicholas T Vozoris Source Type: research

Myofunctional Therapy for OSA: A Meta-Analysis
Expert Rev Respir Med. 2021 Nov 9. doi: 10.1080/17476348.2021.2001332. Online ahead of print.ABSTRACTINTRODUCTION: Myofunctional therapy (MT) improves obstructive sleep apnea (OSA) in patients.AREAS COVERED: We systematically reviewed publications to evaluate MT as a treatment for OSA. We identified relevant articles and performed a meta-analysis on apnea-hypopnea index (AHI) scores, lowest oxygen saturation (LSAT), and Epworth Sleepiness Scale (ESS). Search databases were retained as primary data sources with the search performed through June 18, 2021.EXPERT OPINION: Fifteen studies with 237 patients provided OSA outcomes...
Source: Expert Review of Respiratory Medicine - November 10, 2021 Category: Respiratory Medicine Authors: Sanket Meghpara Moeed Chohan Anuja Bandyopadhyay Conrad Kozlowski Jameson Casinas Clete Kushida Macario Camacho Source Type: research

The Role of Imaging Techniques in Understanding and Evaluating the Long-term Pulmonary Effects of COVID-19
Expert Rev Respir Med. 2021 Nov 3. doi: 10.1080/17476348.2021.2001330. Online ahead of print.ABSTRACTINTRODUCTION: Limited data exist regarding the long-term pulmonary sequelae of COVID-19. Identifying features utilizing multiple imaging modalities engenders a clearer picture of the illness's long-term consequences.AREAS COVERED: This review encompasses the common pulmonary findings associated with different imaging modalities during acute and late remission stages of COVID-19 pneumonia.EXPERT OPINION: Chest x-ray, a common preliminary diagnostic imaging technique, is not optimal for extended care due to limited tissue con...
Source: Expert Review of Respiratory Medicine - November 3, 2021 Category: Respiratory Medicine Authors: Behnam Rabiee Liesl S Eibschutz Shadi Asadollahi Amit Gupta Shahram Akhlaghpoor Ali Gholamrezanezhad Source Type: research

Current evidence on the effect of highly effective CFTR modulation on interleukin-8 in cystic fibrosis
Expert Rev Respir Med. 2021 Nov 2. doi: 10.1080/17476348.2021.2001333. Online ahead of print.ABSTRACTINTRODUCTION: Cystic fibrosis (CF) is a genetically inherited disease, with mortality and morbidity associated with respiratory disease. The inflammatory response in CF is characterized by excessive neutrophil influx to the airways, mainly due to the increased local production and retention of interleukin-8 (IL-8), a potent neutrophil chemoattractant.AREAS COVERED: : We discuss how the chemokine IL-8 more than any other dominates the inflammatory profile of the airways in CF lung disease. Cystic fibrosis transmembrane condu...
Source: Expert Review of Respiratory Medicine - November 2, 2021 Category: Respiratory Medicine Authors: Michael Williamson Michelle Casey Claudie Gabillard-Lefort Aram Alharbi Yu Qing Jolene Teo Noel G McElvaney Emer Reeves Source Type: research

Reorganizing the respiratory high dependency unit for pandemics
This article reviews under a European expert perspective this topic and proposes an adaptation and optimization of the RHDUs to meet the emergent needs caused by the pandemic emphasizing the role of the expert application of noninvasive respiratory therapies in preventing intubation and ICU access.PMID:34720022 | DOI:10.1080/17476348.2021.1997596 (Source: Expert Review of Respiratory Medicine)
Source: Expert Review of Respiratory Medicine - November 1, 2021 Category: Respiratory Medicine Authors: Juan Fernando Masa Maxime Patout Raffaele Scala Joao Carlos Winck Source Type: research

Severe acute asthma at the Paediatric Intensive Care Unit: can we link the clinical phenotypes to immunological endotypes?
Expert Rev Respir Med. 2021 Oct 28. doi: 10.1080/17476348.2021.1997597. Online ahead of print.ABSTRACTINTRODUCTION: The clinical phenotype of severe acute asthma at the Paediatric Intensive Care Unit (PICU) is highly heterogeneous. However, current treatment is still based on a 'one size fits all approach'.AREAS COVERED: We aim to give a comprehensive description of the clinical characteristics of paediatric patients with severe acute asthma admitted to the PICU and available immunological biomarkers, providing the first steps towards precision medicine for this patient population. A literature search was performed using P...
Source: Expert Review of Respiratory Medicine - October 28, 2021 Category: Respiratory Medicine Authors: Sarah van den Berg Simone Hashimoto Korneliusz Golebski Susanne J H Vijverberg Berber Kapitein Source Type: research

Interstitial lung abnormalities: What do we know and how do we manage?
Expert Rev Respir Med. 2021 Oct 23. doi: 10.1080/17476348.2021.1997598. Online ahead of print.ABSTRACTInterstitial lung abnormalities (ILAs), which refers to mild or subtle non-gravity dependent interstitial changes, may be neglected by some clinicians due to many reasons, such as lack of diagnostic criteria for ILAs, and absence of available treatments and surveillance strategies. However, without intervention, some ILAs may progress to interstitial lung disease (ILD). This review summarizes our current knowledge of this condition and ways of diagnosing it together with with current management. We hope that will lead to b...
Source: Expert Review of Respiratory Medicine - October 25, 2021 Category: Respiratory Medicine Authors: Qi Liu Hai Zhang Baohui Han Handong Jiang Kian Fan Chung Feng Li Source Type: research